Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial.

Trial Profile

Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Sapropterin (Primary)
  • Indications Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2013 Actual patient number for the extension study changed from 35 to 41, as reported by the ClinicalTrials.gov record.
    • 08 Jul 2013 Actual patient number for the extension study changed from 35 to 41, as reported by the ClinicalTrials.gov record.
    • 08 Jul 2013 Completion date of extension trial changed from August 2012 to March 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top